Working… Menu

Study of OBINUTUZUMAB Combined to LENALIDOMIDE for the Treatment of Relapsed/Refractory Follicular and Aggressive B-cell Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01582776
Recruitment Status : Active, not recruiting
First Posted : April 23, 2012
Last Update Posted : August 26, 2019
Information provided by (Responsible Party):
The Lymphoma Academic Research Organisation